The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/175759

Please be advised that this information was generated on 2020-03-07 and may be subject to change.
Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD

Janine A. M. Westerik¹, Esther I. Metting², Job F. M. van Boven², Waling Tiersma¹, Janwillem W. H. Kocks² and Tjard R. Schermer¹*

Abstract

Background: COPD often coexists with chronic conditions that may influence disease prognosis. We investigated associations between chronic (co)morbidities and exacerbations in primary care COPD patients.

Method: Retrospective cohort study based on 2012–2013 electronic health records from 179 Dutch general practices. Comorbidities from patients with physician-diagnosed COPD were categorized according to International Classification of Primary Care (ICPC) codes. Chi-squared tests, uni- and multivariable logistic, and Cox regression analyses were used to study associations with exacerbations, defined as oral corticosteroid prescriptions.

Results: Fourteen thousand six hundred three patients with COPD could be studied (mean age 67 (SD 12) years, 53% male) for two years. At baseline 12,826 (88%) suffered from ≥1 comorbidities, 3263 (22%) from ≥5. The most prevalent comorbidities were hypertension (35%), coronary heart disease (19%), and osteoarthritis (18%). Several comorbidities showed statistically significant associations with frequent (i.e., ≥2/year) exacerbations: heart failure (odds ratio [OR], 95% confidence interval: 1.72; 1.38–2.14), blindness & low vision (OR 1.46; 1.21–1.75), pulmonary cancer (OR 1.85; 1.28–2.67), depression 1.48; 1.14–1.91), prostate disorders (OR 1.50; 1.13–1.98), asthma (OR 1.36; 1.11–1.70), osteoporosis (OR 1.41; 1.11–1.80), diabetes (OR 0.80; 0.66–0.97), dyspepsia (OR 1.25; 1.03–1.50), and peripheral vascular disease (OR 1.20; 1.00–1.45). From all comorbidity categories, having another chronic respiratory disease beside COPD showed the highest risk for developing a new exacerbation (Cox hazard ratio 1.26; 1.17–1.36).

Conclusion: Chronic comorbidities are highly prevalent in primary care COPD patients. Several chronic comorbidities were associated with having frequent exacerbations and increased exacerbation risk.

Background

Although nowadays healthcare systems are largely configured to manage individual diseases rather than multimorbidity, there is an increasing awareness of the importance of comorbidities in patients with chronic conditions [1]. Chronic obstructive pulmonary disease (COPD), a prevalent chronic respiratory condition, is a major cause of morbidity and mortality worldwide [2]. In the past decade several studies have shown that COPD often coexists with other diseases, [3, 4] and that comorbidity is associated with poorer clinical outcomes [4, 5]. Some of these comorbidities arise independently of COPD, whereas others may be causally related, either through shared risk factors (smoking, aging) or shared pathophysiology, as a complication of COPD, or due to medication side effects.

Several associations between COPD and particular comorbidities have been shown. Cardiovascular disease, metabolic syndrome, skeletal muscle dysfunction, osteoporosis, depression and lung cancer are all highly prevalent among patients with any severity of COPD, and cross-sectional studies have shown their significant impact on patients’ health-related quality of life [2, 6, 7]. Most of the research on comorbidity in COPD comes from studies in secondary care populations, thus representing patients in the more severe part of the COPD severity spectrum [4]. However, in most developed countries, the vast...
majority of patients with COPD are managed in primary care. Studies performed in general practice settings report that 21 to 74% of patients with COPD suffer from two or more additional chronic diseases [6, 8].

As COPD is a progressive disease, factors that influence its prognosis are important to consider when managing patients. Since exacerbation frequency is a known predictor of COPD progression, [2] it is important to know what the potential impact of comorbidities on the risk of exacerbations is. Recently Putcha et al. reported a model in which the number of comorbid conditions predicted dyspnea and exacerbation risk [9]. This prediction model does, however, not take into account which particular comorbid conditions are associated with exacerbation risk. Other previous studies have predominantly looked at mortality as the outcome of interest, [5, 10, 11] but from a patient management perspective it is important that physicians consider comorbidities that influence potentially modifiable prognostic factors like exacerbation rate in their treatment decisions. Therefore, the aim of the current study was to explore associations between a wide range of comorbid chronic conditions and exacerbation risk in a real-life cohort of primary care patients with COPD.

Methods
Design and dataset
The study used routine data from a general practice database from the Department of Primary and Community Care at the Radboud University Medical Center, Nijmegen, the Netherlands. De-identified electronic medical records from primary care patients diagnosed with COPD from 179 general practices in the eastern part of the Netherlands were available in the database.

For each registered subject, the following data were extracted: age, sex, all diagnoses using the International Classification of Primary Care (ICPC), extended with Dutch ICPC sub-codes, [12] and all prescribed medication. ICPC-2 or ICD10 coding data were recoded into ICPC-1. Medication prescriptions (i.e., prescription start and end dates, dosage, frequency, and duration) were extracted and categorized using the Anatomical Therapeutic Chemical (ATC) classification system [13]. For the current study only the data on prescriptions for oral corticosteroids were used.

Study population
Subjects aged ≥40 years were included in the study population when they had physician-diagnosed COPD (as labeled with ICPC code R95 in the electronic medical record) before or during the study period. Asthma (ICPC R96) in addition to the COPD code was not an exclusion criterion. The follow-up period covered the years 2012 and 2013. The observation period for patients terminated either at the end of the study period (31 December 2013), or when a subject died or deregistered from the practice.

Comorbidities
The selection of chronic comorbid diseases studied was based on existing literature [1, 14], the authors’ clinical expertise and expert opinions (Nielen MM, Spronk I, Davids R, Korevaar JC, Poos MJ, Hoeymans N, Opstelten W, van der Sande MAB, Biermans MCJ, Schellevis FG, RA V). A new method for estimating morbidity rates based on routine electronic medical records in primary care, submitted). We considered all chronic diseases as comorbidities, regardless whether the disease had been diagnosed before the COPD diagnosis or thereafter. Apart from all ‘obligatory’ chronic diseases we also included several recurrent diseases (i.e., depression, anxiety, anemia, dyspepsia, urinary tract infection) which could potentially influence COPD outcomes. After reaching consensus about these recurrent comorbidities within the research team, ICPC (sub)codes were linked (see Appendix 1). Selection of the recurrent comorbidities in our population was based on the patient’s history in terms of these particular ICPC codes. To define whether a history of ICPC codes was relevant or irrelevant for the aim of the study, we added specific selection criteria based on published clinical guidelines for the respective diseases (see Appendix 1).

Finally, a total of 82 chronic comorbid conditions were selected and included in the analyses. The comorbidities were clustered and analyzed based on their ICPC codes into the following 14 categories: respiratory; cardiovascular; digestive; endocrine; metabolic/nutrition; musculoskeletal; neurologic; psychiatric; urogenital; blood (−forming organs)/lymphatics; infectious; eye/ear/skin; non-pulmonary cancer; and pulmonary cancer. Low prevalence categories were merged (see Appendix 2). To restrict ourselves, we focused on conditions with a high prevalence and cardiopulmonary comorbidities (other than COPD) with a lower prevalence (7 conditions, see Table 2). High-prevalent comorbidities (19 conditions), further referred to as ‘frequent comorbidities,’ were defined as being present in ≥5% of the study population. This resulted in a total of 26 comorbidities remaining for further analyses.

Outcomes
The outcomes for the study were (i) prevalence of comorbidities in the study population, (ii) annual rate of exacerbations (dichotomized as <2 versus ≥2 exacerbations/year based on the cumulated 2012/13 data), and (iii) time (in days) until first exacerbation. An exacerbation was defined as a prescription of oral corticosteroids (i.e., prednisolone (ATC H02AB06) or prednisone (ATC H02AB07)) with a minimum daily dose of 20 mg for a minimum duration of 5 days and a maximum duration...
of 15 days (based on Dutch GP guidelines for treatment of COPD exacerbations [15]). As there is no consensus in the literature regarding a cut-off to differentiate between relapse of an earlier exacerbation and a new exacerbation, [16] we considered a subsequent prednisolone prescription after an oral corticosteroid-free interval of ≥14 days since the end-date of the previous prescription as a new exacerbation.

**Statistical analysis**

Analyses were performed with SPSS statistical software (version 22, IBM SPSS Statistics, Feltham, Middlesex, UK) and Microsoft Excel 2007 (Microsoft Corporation, Redmond, Washington, US). Statistically significant results were defined as \( p < 0.05 \). Patients’ baseline characteristics and comorbidity prevalence rates were calculated. We performed Chi-square tests for categorized variables and independent t-tests for continuous variables to analyze differences between the subgroups with <2 and ≥2 exacerbations per year.

We explored associations between comorbidities and exacerbation risk using univariable analyses. Hazard ratios for comorbidities were calculated using Cox regression, in which the time variable consisted of time to the first exacerbation. Data from patients who died or were otherwise lost to follow up were right-censored. Subsequently, all frequent and cardiopulmonary comorbidities (Table 2), age, and gender were included as covariates in multivariate Cox regression analyses. The model was reduced through backward exclusion to produce a final model that consisted of only non-collinear, independently associated, statistically significant covariates. The same modeling approach was used for comorbidity categories using all other categories, with age and gender as covariates.

In addition, we performed multivariable logistic regression analyses to calculate odds ratio’s (ORs) with the dichotomous indicator variable for exacerbation frequency (<2 versus ≥2 exacerbations/year) as the dependent variable. Predictor variables in the logistic models were: all frequent comorbidities, all cardiopulmonary comorbidities, gender, and age. This modeling approach was also used to analyze the 14 categories of comorbidity.

**Results**

**Study population**

Overall, data of 16,427 subjects diagnosed with COPD were available for analyses. Of these patients, 1824 (11.1%) were lost to follow-up during the 2-year study period. Reason for loss to follow-up was known for 800 (44.5%) of these patients, with death being the predominant reason. Table 1 shows baseline characteristics of the patients with complete follow-up (i.e., the final study population, \( n = 14,603 \)). Mean (SD) age was 66.5 (11.5) years and 53% were males. At baseline, 89.1% of patients suffered from ≥1 chronic comorbid conditions, while 23.1% had ≥5 comorbidities. Most prevalent comorbid conditions were hypertension (35.2%), coronary heart disease (19.2%), osteoarthritis (17.6%), diabetes (17.3%), and peripheral vascular disease (14.3%). Table 2 shows the prevalence rates of the frequent and cardiopulmonary comorbidities. Table 3 shows the prevalence of ICPC-categorized comorbidities.

During the 2-year study period the mean number of exacerbations per patient was 0.72 (SD 1.5). 68% of patients had no exacerbation and 5.7% had ≥4 exacerbations during the study period.

**Associations between comorbidities and exacerbation frequency**

Tables 2 and 3 show the univariable associations between comorbidities and comorbidity categories and the exacerbation frequency subgroups, respectively. Overall, patients with one or more comorbid conditions more often had ≥2 exacerbations/year compared to patients without any comorbidity (5.9% vs 4.0%, \( p = 0.001 \)). Patients with any other chronic respiratory disease next to their COPD, \( n = 2,294, 15.7\% \) more often had ≥2 exacerbations per year compared to patients without respiratory comorbidity (8.2% vs 5.7%, \( p < 0.001 \)).

Univariable logistic regression analysis showed that COPD patients with pulmonary cancer had 1.81 higher odds for ≥2 exacerbations per year compared to patients without pulmonary cancer (Fig. 1, \( p = 0.002 \)). Patients who, next to their COPD, also suffered from asthma, blindness or low vision, coronary heart disease, depression, dyspepsia, heart failure, osteoporosis or osteopenia, peripheral vascular disease, or prostate disorders, had a higher risk of having frequent exacerbations compared to those who did not suffer from these comorbid conditions (Fig. 1).

Table 4 lists the comorbidities and comorbidity categories significantly associated with having ≥2 exacerbation per year. In the multivariable logistic regression analysis, among the statistically significant associations, the highest ORs for having ≥2 exacerbations per year were observed for pulmonary cancer (OR 1.85; 95% CI 1.28–2.67), heart failure (OR 1.72; 1.38–2.14), prostate disorders (OR 1.50; 1.13–1.98) and blindness/low vision (OR 1.46; 1.21–1.75) as comorbid conditions (Table 4). Dislipidemia was not statistically significant, but did show a trend, with an OR of 0.81 (95% CI 0.65–1.01, \( p = 0.071 \)). When looking at comorbidity categories, patients
with other chronic respiratory conditions (OR 1.37; 1.15–1.64) and psychiatric comorbidities (OR 1.35; 1.13–1.60) were at highest risk for frequent exacerbations.

**Time to first exacerbation**
Table 5 summarizes the results from the Cox regression analyses. Among the statistically significant associations, the comorbid conditions with the highest risk of developing a first exacerbation were recurrent sinusitis (Cox hazard ratio 1.53; 1.05–2.24), bronchiectasis/chronic bronchitis (HR = 1.50; 1.31–1.73) and heart failure (1.41; 1.29–1.55). For dislipidemia a non-statistically HR of 0.92 was observed (p = 0.067, 95% CI 0.85–1.00). Having another chronic respiratory disease beside COPD was also associated with risk of developing a first exacerbation (Cox hazard ratio 1.26; 1.17–1.36), see Fig. 2.

**Discussion**
In this paper we explored the prevalence of comorbid chronic conditions and associations with exacerbation risk in a real-life cohort of primary care COPD patients. Our findings support the notion that comorbidities are rather rule than exception in patients with COPD [4], with 88% having at least one other chronic disease. Several comorbidities were associated with having frequent exacerbations, with heart failure, blindness/low vision and pulmonary cancer showing the strongest associations in terms of statistical significance. In contrast, diabetes was associated with a lower risk of having frequent exacerbations. Bronchiectasis/chronic bronchitis, heart failure and depression were the strongest predictors for developing a new exacerbation.
Comparison with existing literature

Previous research has shown that cardiovascular, psychiatric, and metabolic comorbidity are highly prevalent in COPD patients [8, 17] and our results confirm these findings. In addition to the finding by Rutten et al. [18] that unrecognized heart failure is rather common in elderly patients with stable COPD, our data also indicate that heart failure may increase the risk of having frequent exacerbations. Recent clinical trial data have shown correlations between several comorbidities and mortality risk if a COPD patient is admitted to hospital with an acute exacerbation [19, 20]. Our observations support the association between chronic comorbidity and exacerbation risk in a primary care study population, i.e., the COPD population without selection of any kind, which is unprecedented and impossible to derive from clinical trial populations [21].

We observed a trend towards statistical significance that COPD patients with dislipidemia had less frequent exacerbations compared to patients without dislipidemia (HR 0.92; *p* = 0.067). This observation seems to be in line with findings by Ingebrigtsen et al., who recently reported that statin use for treatment of dislipidemia was associated with reduced odds of exacerbations in individuals with COPD [22] and findings by Chan et al.

| Table 2 Prevalence of frequent and cardiopulmonary comorbidity in the study population, sorted from highest to lowest prevalence rate |
|---|
| Frequent comorbidity | Total study population, *n* = 14,603 | Patients with <2 exacerbations/year, *n* = 13,709 | Patients with ≥2 exacerbations/year, *n* = 894 | p-value |
| Hypertension | 5,116 (35.0) | 4,805 (35.2) | 311 (34.8) | 0.873 |
| Coronary heart disease | 2,759 (18.9) | 2,569 (18.7) | 191 (21.4) | 0.051 |
| Osteoarthritis | 2,570 (17.6) | 2,402 (17.5) | 168 (18.8) | 0.334 |
| Diabetes | 2,464 (16.9) | 2,330 (17.0) | 134 (15.0) | 0.120 |
| Peripheral vascular disease | 2,031 (13.9) | 1,897 (14.8) | 150 (16.8) | 0.006 |
| Blindness & low vision | 1,938 (13.3) | 1,772 (12.9) | 166 (18.6) | <0.001 |
| Dyslipidemia, gastroesophageal reflux | 1,645 (12.6) | 1,703 (12.4) | 142 (15.9) | 0.003 |
| Stroke & transient ischaemic attack | 1,357 (9.3) | 1,259 (9.2) | 98 (11.0) | 0.076 |
| Chronic kidney disease | 1,360 (9.3) | 1,263 (9.2) | 97 (10.9) | 0.103 |
| Asthma | 1,305 (8.9) | 1,202 (8.8) | 103 (11.5) | 0.005 |
| Hearing loss | 1,144 (7.8) | 1,078 (7.9) | 66 (7.4) | 0.604 |
| Heart failure | 1,048 (7.2) | 943 (6.9) | 105 (11.7) | <0.001 |
| Atrial fibrillation | 1,044 (7.1) | 964 (7.0) | 80 (8.9) | 0.031 |
| Skin cancer | 913 (6.3) | 862 (6.3) | 51 (5.7) | 0.485 |
| Osteoporosis/osteopenia | 884 (6.1) | 801 (5.8) | 83 (9.3) | <0.001 |
| Thyroid disorder | 808 (5.5) | 757 (5.5) | 51 (5.9) | 0.817 |
| Depressetc | 800 (5.5) | 729 (5.3) | 71 (7.9) | 0.001 |
| Prostate disorders | 784 (5.4) | 719 (5.2) | 65 (7.3) | 0.009 |
| Cardiopulmonary comorbidity | | | | |
| Heart valve disease | 568 (3.9) | 528 (3.9) | 40 (7.8) | 0.035 |
| Bronchiectasis/chronic bronchitis | 414 (2.8) | 379 (2.8) | 35 (3.9) | 0.045 |
| Pulmonary cancer | 317 (2.2) | 284 (2.1) | 33 (3.7) | 0.001 |
| Sleep apnea syndrome | 173 (1.2) | 161 (1.2) | 12 (1.3) | 0.653 |
| Other chronic pulmonary disease | 157 (1.1) | 148 (1.1) | 9 (1.0) | 0.838 |
| Recurrent sinusitis | 54 (0.4) | 49 (0.4) | 5 (0.6) | 0.335 |
| Congenital cardiovascular anomaly | 32 (0.2) | 28 (0.2) | 4 (0.4) | 0.132 |

*a*COPD population with complete data available, patients lost to follow-up (*n* = 1,824) excluded

*p*-values displayed are calculated for the difference between the subgroup <2 versus ≥2 exacerbations/year Chi-square tests for categorized variables. *p* < 0.05 was considered statistically significant.
hyperlipidemia in COPD was associated with decreased incidence of pneumonia and mortality in retrospective analyses of health insurance data [23]. Intuitively, the observed lower risk of frequent exacerbations in COPD patients with comorbid diabetes might be sought in GPs’ reluctance to prescribe oral corticosteroids in these patients because the impact this may have on glucose levels, but a survey among Dutch GPs showed that most of them do not adjust treatment of exacerbations to the presence of diabetic comorbidity [24]. Gastroesophageal reflux disease (OR = 1.25 (95% CI 1.03–1.50) in our analyses) was recognized as a significant predictor of acute exacerbations of COPD in a recent review by Lee et al [25]. A relationship between prostate disorders and exacerbations has not been described in the literature, but might be related to use of inhaled anticholinergics.

### Strengths and limitations

A strength of this study is the inclusion of >14 thousand COPD patients from a real-life, unbiased primary care setting. However, the main strength is not so much the uniqueness or even the size of our dataset. Other existing general practice databases essentially contain the same, or even more detailed data regarding diagnoses and medication prescriptions, [26–29] but the meticulousness with which we have looked at ALL chronic comorbidity, including recurrent episodes of conditions that are not necessarily chronic in all patients, seems unprecedented. Moreover, other existing databases with real-life general practice COPD data mainly stem from the UK and Denmark, and now there is also one available from the Netherlands. We intentionally applied minimal exclusion criteria in order to maximize generalizability of the results. Another strength is the wide range of chronic comorbidities investigated, summing up to a total of 82 conditions. Apart from all commonly known chronic comorbid diseases, we also included several recurrent diseases (i.e., depression, anxiety, anemia, dyspepsia, urinary tract infection) and applied criteria to define their chronicity based on disease specific guidelines (see Appendix 1). Inclusion of patients with recurrent diseases seems relevant when studying risk factors for COPD exacerbations, but has not been done in previous studies.

Our study was based on patients’ medical records in general practice. Limited agreement between medical record-based and objectively identified comorbidities of COPD [30] and undiagnosed comorbidity in COPD patients is common [18, 31]. This may have resulted in underestimation of the presence of comorbidity in our

| Comorbidity category                      | Patients with <2 exacerbations/year | Patients with ≥2 exacerbations/year | p-value |
|------------------------------------------|-------------------------------------|-------------------------------------|---------|
| Cardiovascular                           | 8,516 (58 · 3)                      | 7,955 (58 · 0)                      | 0 · 006 |
| Endocrine, metabolic and nutrition       | 4,856 (33 · 3)                      | 4,568 (33 · 3)                      | 0 · 496 |
| Musculoskeletal                          | 3,588 (24 · 6)                      | 3,337 (24 · 3)                      | 0 · 012 |
| Eye and ear                              | 2,984 (20 · 4)                      | 2,762 (20 · 1)                      | 0 · 001 |
| Digestive                                | 2,801 (19 · 2)                      | 2,597 (18 · 9)                      | 0 · 004 |
| Urogenital (male and female)             | 2,330 (16 · 0)                      | 2,146 (15 · 7)                      | <0 · 001|
| Psychiatric                              | 2,271 (15 · 6)                      | 2,092 (15 · 3)                      | <0 · 001|
| Non-pulmonary cancer                     | 2,203 (15 · 1)                      | 2,071 (15 · 1)                      | 0 · 782 |
| Respiratory (excl · pulmonary cancer)    | 1,998 (13 · 7)                      | 1,839 (13 · 4)                      | <0 · 001|
| Skin                                     | 1,395 (9 · 6)                       | 1,314 (9 · 6)                       | 0 · 605 |
| Neurological                             | 413 (2 · 8)                         | 389 (2 · 8)                         | 0 · 789 |
| Pulmonary cancer                         | 317 (2 · 2)                         | 284 (2 · 1)                         | 0 · 001 |
| Blood (forming organs) and lymphatics    | 106 (0 · 7)                         | 97 (0 · 7)                          | 0 · 307 |
| Infectious                               | 87 (0 · 6)                          | 80 (0 · 6)                          | 0 · 453 |

ICPC International Classification of Primary Care

*Total COPD population, with patients who were lost to follow-up (n = 1,824) excluded

*p-values displayed are calculated for the difference between the group <2 versus ≥2 exacerbations/year. We performed Chi-square tests for categorized variables. p-value <0 · 05 was considered statistically significant
Fig. 1 Comorbidome of comorbidities in the COPD study population (n = 14,603). Results are from univariable (upper panel) and multivariable (lower panel, corrected for age, gender and the other comorbidities) logistic regression analysis. (Diameter of the coloured circles represents the prevalence of each comorbidity. Proximity to the black centre of the circle represents stronger positive association (OR) with ≥2 exacerbation per year. The dashed circle represents an OR of 1. Comorbidities marked bold were statistically significantly (i.e., p < 0.05) associated with increased or decreased risk. In the multivariable model covariates were sequentially dropped until only statistically significant covariates remained. Comorbidities outside the dashed circle were negatively associated (i.e., ‘protective’) with ≥2 exacerbation/year. Comorbidities with prevalence <5% were not analysed). CKD: chronic kidney disease. COPD: chronic obstructive pulmonary disease. GERD: gastroesophageal reflux disease. TIA: transient ischemic attack.
study population. The use of real-life data presents limitations, for instance the fact that patients’ smoking history and lung function could not be included because this information is not consistently and uniformly documented in general practice medical records. We chose to limit the analyses to comorbidities with a relatively high (i.e., ≥5%) prevalence. This may mean that comorbidities that are related to increased exacerbation risk but have a low prevalence rate in the COPD patient population were missed.

We defined an exacerbation as an oral corticosteroid prescription, which is the recommended treatment for acute exacerbations in Dutch COPD guidelines [15]. Consequently, mild exacerbations treated with bronchodilators only are not included in our analyses. Oral steroid prescriptions during GP out-of-office hours, emergency department visits and hospitalizations, and prescriptions by pulmonary specialists may not always have been included for all patients, as these are not automatically added to patients’ medical records in all electronic patient record systems. Because there is no international consensus about a definition that discriminates relapse of an earlier exacerbation from a new one, our (arbitrary) choice to use an interval of ≥14 days since the end date of the previous oral steroid prescription may have led to under- or overestimation of the number of exacerbations. Unfortunately, the rather crude prescription information did not allow us to look at the impact of comorbidities on the duration or progression of exacerbations. Although observational studies such as ours lack the rigorous internal validity that is typical for randomized controlled trials, they provide valuable insight into comorbidity prevalence in COPD and its relation with an important outcome, i.e., exacerbations. As such, our findings should be considered in conjunction with those arising from other study designs, including randomized trials.

Table 4 Comorbidities associated with ≥2 exacerbations/year versus <2 exacerbations/year in COPD patients, corrected for age and sex (multivariable results), sorted by p-value

| Comorbid conditions | Odds ratio (95%CI) | p-value |
|---------------------|-------------------|--------|
| Heart failure       | 1.72 (1.38–2.14)  | <0.001 |
| Blindness & low vision | 1.46 (1.21–1.75)  | <0.001 |
| Pulmonary cancer    | 1.85 (1.28–2.67)  | 0.002  |
| Depression          | 1.48 (1.14–1.91)  | 0.003  |
| Prostate disorders  | 1.50 (1.13–1.98)  | 0.004  |
| Asthma              | 1.36 (1.11–1.70)  | 0.004  |
| Osteoporosis/osteopenia | 1.41 (1.11–1.80)  | 0.006  |
| Diabetes            | 0.80 (0.66–0.97)  | 0.020  |
| Dyspepsia, gastroesophageal reflux | 1.25 (1.03–1.50) | 0.023  |
| Peripheral vascular disease | 1.20 (1.00–1.45) | 0.049  |

Comorbidity categories

| Respiratory (excl. pulmonary cancer) | 1.37 (1.15–1.64) | <0.001 |
| Psychiatric                        | 1.35 (1.13–1.60) | <0.001 |
| Urogenital (male and female)       | 1.34 (1.12–1.60) | <0.001 |
| Eye and ear                        | 1.25 (1.06–1.47) | 0.007  |
| Endocrine, metabolic and feeding   | 0.85 (0.73–0.99)  | 0.032  |
| Cardiovascular                     | 1.17 (1.01–1.36)  | 0.037  |

Table 5 Comorbidities associated with development of a first exacerbation in the study population, corrected for age and sex (results from multivariable Cox regression analysis), sorted by p-value

| Comorbidity | Odds ratio (95%CI) | p-value |
|-------------|-------------------|--------|
| Bronchiectasis/chronic bronchitis | 1.50 (1.31–1.73) | <0.001 |
| Heart failure | 1.41 (1.29–1.55) | <0.001 |
| Depression    | 1.34 (1.20–1.50) | <0.001 |
| Atrial fibrillation | 1.27 (1.16–1.40) | <0.001 |
| Asthma        | 1.24 (1.14–1.36) | <0.001 |
| Peripheral vascular disease | 1.15 (1.07–1.24) | <0.001 |
| Prostate disorders | 1.20 (1.04–1.45) | 0.002  |
| Blindness & low vision | 1.11 (1.03–1.20) | 0.009  |
| Coronary heart disease | 1.10 (1.02–1.17) | 0.011  |
| Dyspepsia, gastroesophageal reflux | 1.10 (1.02–1.20) | 0.013  |
| Pulmonary cancer | 1.23 (1.04–1.45) | 0.016  |
| Recurrent sinusitis | 1.53 (1.05–2.24) | 0.028  |
| Osteoporosis/osteopenia | 1.12 (1.01–1.25) | 0.037  |
| Respiratory (excl. pulmonary cancer) | 1.26 (1.17–1.36) | <0.001 |
| Urogenital (male and female)       | 1.18 (1.10–1.27) | <0.001 |
| Cardiovascular                     | 1.16 (1.08–1.24) | <0.001 |
| Mental health                      | 1.16 (1.08–1.24) | <0.001 |
| Eye and ear                        | 1.09 (1.02–1.16) | 0.013  |
| Digestive                          | 1.07 (1.00–1.15) | 0.042  |
Clinical implications
Better knowledge about the role that comorbidity plays in COPD exacerbation risk may contribute to lower exacerbation rates in COPD patients through patient-tailored and systems medicine approaches. In turn, reduction of exacerbations may improve patients’ quality of life and prevent disability, hospitalizations, and mortality. A challenge for researchers is to find ways to enable physicians to take comorbidity into account when assessing COPD patients’ exacerbation risk. Putcha et al. developed a simple score that includes 14 comorbidities, where one point increase in comorbidity count was associated with 21% higher exacerbation risk [9]. However, their comorbidity score does not include comorbidities such as asthma, lung cancer and depression, while our results indicate that these comorbidities are also related to exacerbation risk. Neither does Putcha’s score take differences in exacerbation risk for different comorbidities into account. This highlights the importance of including a wide range of comorbid chronic conditions like we did in our study.

Beside Putcha’s comorbidity score, several prognostic indices to support COPD patient care have been developed, [32] most of them predicting prognosis in terms of mortality or hospitalization. Only few indices predict exacerbation risk and only one (the DOSE index [33]) has been developed and validated in primary care [34]. Comorbidity is not included in the existing prognostic indices, with the exception of the COTE index, which assesses mortality and not exacerbation risk [10, 11]. Our results may contribute to the development of a prognostic index that connects comorbidities with exacerbation risk to identify patients at highest risk, thereby potentially reducing disease progression.

Conclusion
We have confirmed that many patients with COPD are affected by chronic comorbidities. Several highly prevalent as well as cardiopulmonary comorbidities appear to be independently associated with the risk of suffering from frequent exacerbations in our unbiased primary care patient population. Apart from clinical COPD guidelines advising that comorbidities should be diagnosed and treated appropriately, insight in patients’ comorbidity patterns could also be used to identify those that are more likely to suffer from frequent exacerbations. Further research is needed to assess opportunities of implementation of this knowledge in routine care, so that patient-centered COPD care that also takes comorbidity into account can become the standard. Ultimately this may contribute to reducing disease progression and reduce the significant burden that COPD and its exacerbations puts on patients and healthcare systems.
### Appendix 1

**Table 6** List of 82 comorbidities included in comorbidity selection, sorted by prevalence (%) in the study population

| Comorbidity                                      | Prevalence (%) | Diagnosis                      | ICPC code                  | Inclusion criteria                      |
|--------------------------------------------------|----------------|--------------------------------|---------------------------|----------------------------------------|
| Hypertension                                     | 35.2           | Hypertension                   | K86, K87                  | ICPC code before 1-1-12                |
| Coronary heart disease                           | 19.2           | Myocardial infarction/other    | K75, K76, K76.02, K76.01 | ICPC code before 1-1-12                |
| Angina Pectoris                                  |                |                                |                           |                                        |
| Osteoarthritis                                   | 17.6           | Artrose/spondylose wervelkolom | L84, L84.01, L84.02       | ICPC code before 1-1-12                |
| Diabetes                                         | 17.3           | DM1, DM2                       | T90, T90.01, T90.02       | ICPC code before 1-1-12                |
| Peripheral vascular disease                      | 14.3           | Atherosclerose                  | K91                       | ICPC code before 1-1-12                |
| Blindness & low vision                           | 13.8           | (Diabetic/hypertensive) retinopathy | F83, F83.01, F83.02    | ICPC code before 1-1-12                |
| Dyspepsia, Gastroesophageal reflux (GERD)        | 12.6           | Stomach ulcer                   | D86.01                    | ICPC code before 1-1-12 AND (recode OR connection to episode) 12 months after first ICPC [35] |
| Dislipidemia                                     | 11.5           | Hypercholesterolemia/          | T93, T93.01, T93.02, T93.03, T93.04 | ICPC code before 1-1-12               |
| Stroke & transient ischaemic attack              | 9.7            | TIA (transient ischemic        | K99                       | ICPC code before 1-1-12                |
| chronic heart attack                             |                | accident)                      |                           |                                        |
| Chronic kidney disease                           | 9.5            | Renal dysfunction               | U99, U99.01               | ICPC code before 1-1-12                |
| Asthma                                           | 8.5            | Asthma                         | R96, R96.01, R96.02       | ICPC code before 1-1-2012 AND (recode OR connection to episode) 24 months after first ICPC code [36] |
| Hearing loss                                     | 8.1            | Deafness                        | H84, H86, H85             | ICPC code before 1-1-12                |
| Heart failure                                    | 7.9            | Congestive heart failure        | K77, K77.01, K77.02       | ICPC code before 1-1-12                |
| Atrial fibrillation                              | 7.5            | Atrial fibrillation/           | K78                       | ICPC code before 1-1-12                |
| Skin cancer                                      | 6.3            | Skin cancer                     |                           | ICPC code before 1-1-12                |
| Condition                                                      | Prevalence (%) | ICPC Code Before | Recode OR Connection to Episode |
|---------------------------------------------------------------|----------------|------------------|---------------------------------|
| Osteoporosis/osteopenia                                      | 6.3            | L95, L95.01, L95.02 | ICPC code before 1-1-12          |
| Depression                                                   | 5.6            | P76, P76.01       | ICPC code before 1-1-12 AND (recode OR connection to episode) 24 months after first ICPC code [37, 38] |
| Thyroid disorder                                             | 5.6            | T86              | ICPC code before 1-1-12          |
| Psooriasis                                                   | 4.6            | S91              | ICPC code before 1-1-12          |
| Obesity                                                      | 4.4            | T82              | ICPC code before 1-1-12          |
| Anxiety                                                      | 4.3            | P75              | ICPC code before 1-1-12 AND (recode OR connection to episode) 24 months after first ICPC code [39] |
| Phobia                                                       |                | P79.01           | ICPC code before 1-1-12 AND (recode OR connection to episode) 24 months after first ICPC code [39] |
| Anxiety disorder                                             |                | P74, P74.01, P74.02 | ICPC code before 1-1-12 AND (recode OR connection to episode) 24 months after first ICPC code [39] |
| Obsessive - compulsive disorder                              |                | P79.02           | ICPC code before 1-1-12 AND (recode OR connection to episode) 24 months after first ICPC code [39] |
| (chronic) functional somatic symptoms                        |                | P01, P78         | ICPC code before 1-1-12 AND (recode OR connection to episode) 24 months after first ICPC code [39] |
| Post traumatic stress disorder                               |                | P02.01           | ICPC code before 1-1-12 AND (recode OR connection to episode) 24 months after first ICPC code [39] |
| Eczema                                                       | 4.1            | S87              | ICPC code before 1-1-12          |
| Heart valve disease                                          | 3.9            | K83, K83.01, K83.02 | ICPC code before 1-1-12          |
| Diverticular disease of intestine                            | 3.9            | D92              | ICPC code before 1-1-12          |
| Alcohol problems                                             | 3.9            | P15, P15.01, P15.02, P15.03, P15.04, P15.05, P15.06 | ICPC code before 1-1-12 |
| Rheumatoid arthritis, other inflammatory, polyarthropathies & systemic connective tissue disorders | 3.7            | L88.01, L88.02, L88 | ICPC code before 1-1-12 |
| Bronchiectasis/chronic bronchitis                            | 2.8            | R91.02, R91.01   | ICPC code before 1-1-12          |
| Irritable bowel syndrome                                     | 2.8            | D93              | ICPC code before 1-1-12          |
| Venous insufficiency                                         | 2.4            | K99.04           | ICPC code before 1-1-12          |
| Varicose ulcer                                               | 2.4            | S97, S97.01      | ICPC code before 1-1-12 AND (recode OR connection to episode) 3 months after first ICPC code [40] |
| Pulmonary cancer                                             | 2.4            | R84              | ICPC code before 1-1-12          |
| Recurrent urinary tract infection                             | 2.3            | U71, U71.01, U71.02 | ICPC code AND (recode OR connection to episode) 23 times/year in 2011, 2012, 2013. Years start with 1e ICPC code. Minimal 8 weeks between each episode [41] |
| Breast cancer                                                | 2.3            | X76, X76.01      | ICPC code before 1-1-12          |
| Comorbidity                        | Prevalence (%) | ICPC Code(s)                      |
|-----------------------------------|----------------|----------------------------------|
| Glaucoma                          | 2.2            | F93, F93.01, F93.02, F93.03, F93.04 |
| Gout                              | 2.0            | T92                              |
| Prostate cancer                   | 1.9            | Y77                              |
| Dementia                          | 1.7            | P70.01, P70, P70.02               |
| Colorectal cancer                 | 1.7            | D75                              |
| Epilepsy                          | 1.4            | N88                              |
| Bladder cancer                    | 1.3            | U76                              |
| Sleep apnea syndrome              | 1.2            | P0601                            |
| Underfeeding/vitamin deficiency    | 1.2            | T91, T05                          |
| Inflammatory bowel disease        | 1.2            | D94, D94.01, D94.02               |
| Personality disorder              | 1.2            | P80, P80.01, P80.02               |
| Prostate disorders                | 1.2            | Y85                              |
| Other chronic pulmonary disease   | 1.1            | R70                              |
| Chronic liver disease             | 1              | D97, D97.04, D97.05               |
| Genitourinary cancer, other       | 0.9            | U75, U77, X77, Y78, Y78.01, Y78.03 |
| Blood (forming organs) and        | 0.8            | B75                              |
| lymphatics disorder               |                | Haemophilia B83.01                |
| Schizophrenia/non-organic         | 0.8            | P72                              |
| psychosis/bipolar disorder        |                | Psychosis non specified P98       |
| Migraine                          | 0.8            | N89                              |
| Cancer oropharynx, oesophageal,    | 0.8            | D77.02, D77.03                    |
| stomach                           |                | Oesophageal cancer D77.01, D77    |
| Other psychoactive substance      | 0.7            | D74                              |
| misuse                            |                | Substance abuse P19, P19.01, P19.02 |
| Parkinson's disease               | 0.6            | N87.01, N87                       |

(Continued)

*ICPC code AND (recode OR connection to episode) ≥ 3 times/year in 2011, 2012, 2013. Years start with 1 one ICPC code. Minimal 22 days between each episode [42].*
Table 6 List of 82 comorbidities included in comorbidity selection, sorted by prevalence (%) in the study population (Continued)

| Comorbidity                                                                 | Prevalence (%) | Code                                                                 |
|----------------------------------------------------------------------------|----------------|----------------------------------------------------------------------|
| Other chronic skin disease/neoplasm (sub)cutis                          | 0.6            | Neoplasm cutis, subcutis non specified S80, S80.01, S81, S83, S83.01, S83.02 ICPC code before 1-1-12 |
|                                                                             |                | Vitiligo/lichen planus S99.04, S99.06 ICPC code before 1-1-12        |
| Viral hepatitis                                                            | 0.6            | Hepatitis B D72.02, D72.04 ICPC code before 1-1-12                   |
|                                                                             |                | Hepatitis C D72.03, D72.05 ICPC code before 1-1-12                   |
|                                                                             |                | Hepatitis D72 ICPC code before 1-1-12                                |
| Uterine cervical cancer                                                    | 0.5            | Uterine cervical cancer X75 ICPC code before 1-1-12                  |
| Learning disability/Mental retardation                                     | 0.4            | Mental retardation P85 ICPC code before 1-1-12                      |
|                                                                             |                | Specified learning problems P24, P24.01, P24.02, P24.03 ICPC code before 1-1-12 |
| Laryngeal/throat cancer                                                    | 0.4            | Laryngeal/throat cancer R85 ICPC code before 1-1-12                  |
| Hodgkin disease                                                            | 0.4            | Hodgkin disease B72, B72.01, B72.02 ICPC code before 1-1-12          |
| Carcinoma, other                                                           | 0.4            | Carcinoma, other D77.04, T71, W72, L71, L71.01                      |
| Chronic sinusitis                                                          | 0.3            | Chronic sinusitis R75.02 ICPC code before 1-1-12                     |
|                                                                             |                | Acute Sinusitis R75.01 en R75 ICPC code before 1-1-12                |
| Glomerulonephritis/nephrosis                                              | 0.3            | Glomerulonephritis U88 ICPC code before 1-1-12                      |
| Congenital cardiovascular anomaly                                         | 0.2            | Congenital cardiovascular anomaly K73, K73.01, K73.02 ICPC code before 1-1-12 |
| Leukaemia                                                                  | 0.2            | Leukaemia B73 ICPC code before 1-1-12                               |
| Lymphoma/multiple myeloma/other blood cancer                              | 0.2            | Lymphoma/multiple myeloma/other blood cancer B74.01, B74 ICPC code before 1-1-12 |
| Anaemia                                                                    | 0.1            | Pernicious/folic acid anaemia B81, B81.01, B81.02 ICPC code before 1-1-12 AND (recode OR connection to episode) 12 months after first ICPC [43] |
|                                                                             |                | Haemolytic anaemia B78, B78.01, B78.02, B78.03 ICPC code before 1-1-12 |
| Anorexia or bulimia                                                       | 0.1            | Anorexia nervosa T06, T06.01, T06.02 ICPC code before 1-1-12         |
| Coeliacia                                                                  | 0.1            | Coeliacie D99.06 ICPC code before 1-1-12                             |
| Endometrial cancer                                                         | 0.1            | Endometrial cancer X77.01 ICPC code before 1-1-12                   |
| Metastases; unknown origin                                                 | 0.1            | Metastases; unknown origin A79 ICPC code before 1-1-12               |
| Multiple sclerosis                                                         | 0.1            | MS (multiple sclerosis) N86 ICPC code before 1-1-12                  |
| Ovarian cancer                                                             | 0.1            | Ovarian cancer X77.02 ICPC code before 1-1-12                       |
| Pancreatic cancer                                                          | 0.1            | Pancreatic cancer D76 ICPC code before 1-1-12                       |
| Testis cancer                                                              | 0.1            | Testis cancer Y78.02 ICPC code before 1-1-12                        |
| Brain cancer (recall: Nervous system cancer)                               | 0.0            | Brain cancer (recall: Nervous system cancer) N74 ICPC code before 1-1-12 |
| HIV/AIDS                                                                   | 0.0            | HIV; AIDS B90, B90.01, B90.02 ICPC code before 1-1-12               |
### Appendix 2

#### Table 7: List of comorbidity categories

| Categories of chronic disease | Disease |
|------------------------------|---------|
| Cardiovascular               | Hypertension  |
|                              | Coronary heart disease |
|                              | Congenital cardiovascular anomaly |
|                              | Heart failure |
|                              | Stroke & transient ischaemic attack |
|                              | Atrial fibrillation |
|                              | Heart valve disease |
|                              | Venous insufficiency |
|                              | Peripheral vascular disease |
| Respiratory                  | COPD |
|                              | Asthma |
|                              | Sleep apnea syndrome |
|                              | Chronic sinusitis |
|                              | Other chronic pulmonary disease |
|                              | Bronchietasis/chronic bronchitis |
| Mental Health                | Depression |
|                              | Anxiety disorder |
|                              | Alcohol problems |
|                              | Other psychoactive substance misuse |
|                              | Schizophrenia/non-organic psychosis/bipolar disorder |
|                              | Anorexia or bulimia |
|                              | Personality disorder |
|                              | Learning disability/Mental retardation |
| Musculoskeletal              | Rheumatoid arthritis, other inflammatory polyarthropathies & systemic connective tissue disorders |
|                              | Gout |
|                              | Osteoporosis/osteopenie |
|                              | Osteoarthritis |
| Eye and Ear                  | Hearing loss |
|                              | Glaucoma |
|                              | Blindness & low vision |
| Urogenital (Male and female) | Chronic kidney disease |
|                              | Glomerulonephritis/nephrosis |
|                              | Recurrent urinary tract infection |
|                              | Prostate disorders |
| Skin                         | Eczema |
|                              | Psoriasis |
|                              | Other chronic skin disease/neoplasm (sub)cutis |

### Table 7: List of comorbidity categories (Continued)

| Categories of chronic disease | Disease |
|------------------------------|---------|
| Digestive                    | Diverticular disease of intestine |
|                              | Dyspepsia, Gastroesophageal reflux |
|                              | Irritable bowel syndrome |
|                              | Inflammatory bowel disease |
|                              | Coeliac |
|                              | Chronic liver disease |
| Endocrine, metabolic and nutrition | Underfeeding/vitamine deficiency |
|                              | Diabetes |
|                              | Dislipidemia |
|                              | Obesity |
|                              | Thyroid disorder |
| Neurological                 | Dementia |
|                              | Epilepsy |
|                              | Migraine |
|                              | Parkinson’s disease |
|                              | Multiple sclerosis |
| Blood (forming organs) and Lymphatics | Anaemia |
|                              | Blood (forming organs) and lymphatics disorder |
| Infectious                   | Viral hepatitis |
|                              | HIV/AIDS |
| Non-pulmonary cancer         | Testis Cancer |
|                              | Cancer ofopharynx, oesophageal, stomach |
|                              | Cancer Colorectal |
|                              | Pancreatic cancer |
|                              | Laryngeal/troat cancer |
|                              | Breast cancer |
|                              | Ovarian cancer |
|                              | Endometrial cancer |
|                              | Uterine cervical cancer |
|                              | Prostate cancer |
|                              | Bladder cancer |
|                              | Genitourinary cancer, other |
|                              | Brain cancer (recall: Nervous system cancer) |
|                              | Hodgkin disease |
|                              | Leukaemia |
|                              | Lymphoma/multiple myeloma/other blood cancer |
|                              | Metastases; unknown origin |
|                              | Carcinoma, other |
|                              | Skin cancer |
| Pulmonary cancer             | Pulmonary cancer |
Appendix 3

Table 8 Baseline characteristics of the initial population of all COPD patients, the patients who were lost to follow-up, and the patients with full follow-up

| Patient characteristics | All COPD patients (n=16,427) | Patients lost to follow-up (n=1,824) | Patients with full follow-up (study population) \( ^* \) (n=14,603) |
|-------------------------|-------------------------------|---------------------------------------|-------------|
| Sex, male, n (%)       | 8,682 (52·9)                 | 933 (51·2)                           | 7,749 (53·1) |
| Age at study baseline, years; mean (SD; range) | 66·9 (11·6; 40–111) | 70·1 (12·0; 40–111) | 66·5 (11·5; 40–110) \( ^\dagger \) |
| Full dataset available (censored data), n (%) | | | |
| Full data available    | 14,603 (88·7)                |                                      |             |
| Deceased               | 541 (3·0)                    | 541 (29·7)                           | N/A         |
| Moved                  | 223 (1·3)                    | 223 (12·2)                           | N/A         |
| Nursing home           | 36 (0·2)                     | 36 (2·0)                             | N/A         |
| Unknown                | 1024 (6·2)                   | 1024 (56·1)                          | N/A         |
| Comorbidity data       |                               |                                      |             |
| Number of comorbid diseases \( ^b \), mean (SD; range) | 3·0 (2·3; 0–20) | 3·4 (2·5; 0–16) | 3·0 (2·3; 0–20) \( ^\dagger \) |
| Number of comorbid diseases categories \( ^b \), n (%) | | | |
| 0                      | 1,951 (11·9)                 | 174 (9·5)                            | 1,777 (12·2) |
| 1 or 2                 | 5,891 (35·9)                 | 586 (32·1)                           | 5,305 (36·6) |
| 3 or 4                 | 4,797 (29·2)                 | 539 (29·6)                           | 4,258 (29·2) |
| 5 and more             | 3,788 (23·1)                 | 525 (28·8)                           | 3,263 (22·3) \( ^\dagger \) |
| Exacerbations data     |                               |                                      |             |
| Number of exacerbations, mean (SD; range) | 0·72 (1·5;0–15) \( ^c \) | 0·46 (1·0;0–11) \( ^c \) | 0·75 (1·5;0–15) |

\( ^{SD} \) standard deviation, \( ^{N/A} \) not applicable
\( ^{p<0·05} \), \( ^{p<0·01} \), \( ^{p<0·001} \)
\( ^{p} \)-values displayed are calculated for the difference between patients lost to follow-up versus patients with full follow-up. Chi-square tests for categorized variables and independent t-tests for continuous variables. \( ^{p<0·05} \) was considered statistically significant
\( ^{b} \)Presence of any type of comorbid disease was assessed at study baseline, i.e. 1 January 2012
\( ^{c} \)Mean number of exacerbations during the study period, 1 January 2012 – 31 December 2013. For the columns ‘all COPD patients’ and ‘Patients lost to follow-up’, these rates cannot be converted into annual rates because of incomplete observation time in the patients who were lost to follow-up

Baseline characteristics of the study population grouped by low (<2/year) versus high (≥2/year) exacerbation rate are reported in Table 1

Acknowledgements
The authors appreciate the statistical support provided by Reinier Akkermans.

Funding
GlaxoSmithKline funded the study with a research grant. The sponsor was not involved in the execution of the study, interpretation of the results, or the writing of this paper. The corresponding author had full access to all data and the final responsibility to submit for publication.

Availability of data and materials
Please contact author for data requests.

Authors’ contributions
TRS initiated the study. JAMW, EM, JFMB, WT, JWHK and TRS designed the study. JAMW, EM and TRS analysed and interpreted data. JAMW and TRS wrote the initial version of the paper. JAMW, EM, JFMB, JWHK and TRS revised the report. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
In the Netherlands, all patients are listed with a general practitioner (GP) and have access to specialized healthcare through this GP. For this database study, approval of an ethics committee was not required.

Author details
\( ^{\dagger} \)Department of Primary and Community Care, Radboud University Medical Center, 117-ELG, Geert Grooteplein Noord 21, Nijmegen 6525 EZ, The Netherlands.
\( ^{\dagger} \)Department of General Practice, Groningen Research Institute for Asthma and COPD (GRIA), University Medical Center Groningen, University of Groningen, HPC FA21, Antonius Deusinglaan 1, Groningen 9713 AV, The Netherlands.

Received: 24 September 2016 Accepted: 18 January 2017
Published online: 06 February 2017

Abbreviations
ATC: Anatomical therapeutic chemical; CKD: Chronic kidney disease; COPD: Chronic obstructive pulmonary disease; GERD: Gastroesophageal reflux disease; GP: General practitioner; ICPC: International classification of primary care; N/A: Not applicable; OR: Odds ratio; SD: Standard deviation; TIA: Transient ischemic attack; UK: United Kingdom; US: United States
References

1. Barnett K, Mercer SW, Norbury M, Watt G, Wyley S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet (London, England). 2012;380(9863):37–45.

2. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2016. Available from: http://www.goldcopd.org/. Accessed 16 Jan 2017.

3. van Manen JG, Ijzermans CJ, Bindels PJ, van der Zee JS, Bottema BJ, Schade E. Comorbidity of pneumonia in patients with a prevalent airway obstruction and controls over the age of 40. J Clin Epidemiol. 2001;54(3):287–93.

4. Negewo NA, McDonald WM, Gibson PG. Comorbidity in chronic obstructive pulmonary disease. Respir Investig. 2015;53(6):269–58.

5. Putcha N, Drummond MB, Wise RA, Harsel NN. Comorbidities and chronic obstructive pulmonary disease: prevalence, influence on outcomes, and management. Semin Respir Crit Care Med. 2015;36(4):575–91.

6. Wijnhoven HA, Kriegsman DM, Hesselink AE, de Haan M, Schellevis FG. The systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–9.

7. Chen W, Thomas J, Sadatsafavi M, Fitzgerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–9.

8. Garcia-Olmos L, Alberquilla A, Ayala V, Garcia-Sagredo P, Morales L, Carmona M, et al. Comorbidity in patients with chronic obstructive pulmonary disease in family practice: a cross sectional study. BMC Fam Pract. 2013;14:11.

9. Putcha N, Puhan MA, Drummond MB, Han MK, Regan FA, Hanania NA, et al. A simplified score to quantify comorbidity in COPD. PLoS One. 2014;9(12):e114438.

10. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–61.

11. de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Divo M, Zulueta JJ, et al. Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. Thorax. 2014;69(9):799–804.

12. Okkes IM, Becker HW, Bernstein RM, Lamberts H. The March 2002 update of sponsored COPD studies: an UNLOCK validation study. PLoS One. 2014;9(3):e90145.

13. Frei A, Muggensturm P, Putcha N, Siebeling L, Zoller M, Buddeke WD, et al. Frequency and relevance of ischemic electrocardiographic findings in patients with chronic obstructive pulmonary disease. Am J Cardiol. 2011;108(11):1699–9.

14. Luijks H, Schermer T, Bor H, van Weel C, Lagro-Janssen T, Biermans M, et al. Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study. PLoS One. 2014;9(3):e90145.

15. Putcha N, Puhan MA, Drummond MB; Han MK, Regan FA, Hanania NA, et al. A simplified score to quantify comorbidity in COPD. PLoS One. 2014;9(12):e114438.

16. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Thorax. 2015;70(1):33–8.

17. Frei A, Muggensturm P, Putcha N, Siebeling L, Zoller M, Buddeke WD, et al. Five comorbidities reflected the health status in patients with chronic obstructive pulmonary disease. Thorax. 2015;70(1):33–8.

18. Van Weel-Baumgarten EM, Van Gelderen MG, Grundmeijer HGLM, Lichtervelde JG, Bongers MM, et al. Management of COPD in the UK primary-care setting: an analysis of Poor agreement between chart-based and objectively identified comorbidities of COPD. Eur Respir J. 2015;46(5):1492–5.

19. Van Weel-Baumgarten EM, Van Gelderen MG, Grundmeijer HGLM, Lichtervelde JG, Bongers MM, et al. Management of COPD in the UK primary-care setting: an analysis of Poor agreement between chart-based and objectively identified comorbidities of COPD. Eur Respir J. 2015;46(5):1492–5.

20. Xu W, Collet JP, Shapiro S, Lin Y, Yang T, Platt RW, et al. Independent effect pulmonary disease in family practice: a cross sectional study. BMC Fam Pract. 2013;14:11.

21. Van Weel-Baumgarten EM, Van Gelderen MG, Grundmeijer HGLM, Lichtervelde JG, Bongers MM, et al. Management of COPD in the UK primary-care setting: an analysis of Poor agreement between chart-based and objectively identified comorbidities of COPD. Eur Respir J. 2015;46(5):1492–5.

22. Ingebrigtsen TS, Marott JL, Nordestgaard BG, Lange P, Hallas J, Vestbo J. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax. 2015;70(1):33–40.

23. Chan MC, Lin CH, Kou YR. Hyperlipidaemia in COPD is associated with decreased incidence of pneumonia and mortality a nationwide health insurance data based retrospective cohort study. Int J Chon Obstruct Pulmon Dis. 2016;11:1053–9.

24. de Vries M, Berendse AJ, Boxveld HE, Kerstjens HA, van der Molen T. COPD exacerbations in general practice: variability in oral prednisolone courses. BMC Fam Pract. 2012;13:3.

25. Lee AL, Goldstein RS. Gastroesophageal reflux disease in COPD: links and risks. Int J Chon Obstruct Pulmon Dis. 2015;10:1935–49.

26. Price D, West D, Brusselle G, Gryffydd-Jones K, Jones R, Miravitlles M, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chon Obstruct Pulmon Dis. 2014;9:889–904.

27. Janssen HJM, Lagro-LAHM, Van Peet PG, Gorter KJ, Van der Pas P, Van der Paardt M, Woutersen-Koch H. [NHG guideline osteoarthritis (first version)]. Huisarts Wet. 2009;52(9):439–53.
43. Bouma M, Burgers J, Drost B, Den Elzen WPJ, Luchtman T, Oosterhuis WP, Woutersen-Koch H, Van Wijk M; NHG-werkgroep Anemie. [NHG guideline anemia (first revision)]. Huisarts Wet. 2014;57(10):528–36.
44. Dekker F, Van Duijn NP, Ongering JEP, Bartelink MEL, Boelman L, Burgers JS, Bouma M, Kurver MJ. [NHG guideline Headache (third revision)]. Huisarts Wet. 2014;57(1):20–31.
45. Venekamp RP, De Sutter A, Sachs A, Bons SCS, Wiersma TJ, De Jongh E. [NHG guideline Acute rhinosinusitis (third revision)]. Huisarts Wet. 2014;57(10):537.